The ongoing scrutiny of pharmacy benefit managers (PBMs) has intensified following the Federal Trade Commission’s (FTC) release of its second interim staff report on these prescription drug intermediaries. In this latest report, the commission has illuminated the significant price markups imposed by major PBMs—CVS Caremark, Express Scripts, and Optum Rx—on specialty generic drugs, including those for critical conditions such as cancer and HIV. This unanimous decision by the FTC commissioners marks another chapter in the growing tensions between the regulatory body and the trio of dominant PBMs.
FTC Chair Lina M. Khan emphasized that the commission will continue its probe into practices that could potentially inflate drug prices and limit access to affordable healthcare, urging for swift action should illegal conduct be discovered. This report follows the FTC’s earlier investigation into the concentration of power within the PBM sector, which had already set a critical tone against these entities. The regulatory push against the PBMs reached a pivotal point when the FTC decided to sue for alleged price gouging on insulin, prompting a subsequent countersuit from the PBMs challenging the constitutionality of the FTC’s legal actions.
The FTC’s recent findings disclosed that between 2017 and 2022, PBMs enforced substantial price increases on a wide array of specialty generic drugs, achieving disproportionately high revenues from affiliated pharmacies. These financial gains amounted to over $7.3 billion above the National Average Drug Acquisition Cost (NADAC) for these drugs, with an additional $1.4 billion stemming from spread pricing strategies. This has drawn notable reactions across the healthcare landscape.
Healthcare leaders have voiced support for the FTC’s efforts, pointing to the report’s implications about the financial burden placed on both employers and patients. Antonio Ciaccia, CEO of 46brooklyn, reflected on the revelations as a validation of efforts to shed light on PBM dynamics, stating that the findings shared in the report echo numerous instances where specialty drugs have been significantly marked up. Ellen Rudolph, CEO of WellTheory, stressed the detrimental impact of these practices on patients and employers, calling for policy reforms to address rampant price hikes.
Conversely, the PBMs largely criticized the report, arguing it portrayed a skewed perspective by focusing on a small segment of specialty drugs. David Whitrap of CVS Health highlighted that the specialty generics in the report accounted for less than 1.5% of their clients’ total drug spend during the analyzed period. Express Scripts expressed that the FTC report did little to tackle the root causes of rising drug prices, while Optum maintained that it remains committed to reducing costs and providing support to patients with complex conditions.
The divide between the healthcare sector’s alignment with the FTC’s findings and the PBMs’ counterarguments reflects a broader discussion about drug pricing practices and the role of PBMs within the healthcare ecosystem. As the FTC continues its scrutiny and legal battles unfold, the discourse surrounding these issues is poised to influence industry practices and policy in the coming months. More information can be found on MedCity News.